Stock NRSN NEUROSENSE THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News NeuroSense Therapeutics Ltd.

Equities

NRSN

IL0011809592

Market Closed - Nasdaq
Other stock markets
 15:59:56 2024-06-28 EDT 		5-day change 1st Jan Change
1.12 USD +9.80% Intraday chart for NeuroSense Therapeutics Ltd. +24.72% +42.68%
06-24 Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm... Our Logo
06-24 NeuroSense Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...
Our Logo
NeuroSense Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
PR
NeuroSense Therapeutics Receives Delisting Notice From Nasdaq
MT
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
PR
NeuroSense Therapeutics : INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Form 6 K
PU
NeuroSense Therapeutics : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 - Form 6-K
PU
NeuroSense Therapeutics : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 - Form 6-K
PU
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit
PR
NeuroSense Partners with PhaseV for ALS Treatment Trial -- Shares Up
MT
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
PR
NeuroSense Therapeutics : Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning - Form 6-K
PU
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
PR
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
CI
NeuroSense Therapeutics Ltd. announced that it has received $4.47 million in funding
CI
NeuroSense to Collaborate With Genetika+ on Alzheimer's Disease Drug Development; Shares Fall
MT
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
PR
NeuroSense Therapeutics Ltd. and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
CI
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
AQ
NeuroSense Therapeutics Ltd. Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRSN Stock
  4. News NeuroSense Therapeutics Ltd.